Phase I clinical trial of a mixed 20 peptides vaccine for castration-resistant prostate cancer (CRPC) - Phase I clinical trial of a mixed 20 peptides vaccine for CRPC

Research Center for Innovative Cancer Therapy, Kurume University School of Medicine0 个研究点目标入组 15 人开始时间: 2012年6月27日最近更新: 2023年10月17日

试验速览

暂无简介。

•The following patients must be excluded: 1) Patients who had received pre-therapies including radiotherapy, chemotherapy or immunotherapy within 28 days before the treatment. 2) Patients who had received radiotherapy to prostate within the last 1 year before the treatment. 3) Immunosuppressive treatment using a systematic steroid within the last 1 year was not permitted except for using low-dose steroid. 4)Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 5) Patients with active multiple cancers. 6) Patients with the past history of severe allergic reactions. 7)Patients who do not agree with contraception during treatment and until 70 days after treatment. 8) Patients who had enrolled in another trial within 6 months or who are treating in another trial. 9) Patients who had received any peptides consist of a mixed 20 peptides (KRM-20). 10)Patients who are difficult to participate in this trial because of psychiatric symptoms. 11)Patients who are judged inappropriate for the clinical trial by doctors.

发起方

Research Center for Innovative Cancer Therapy, Kurume University School of Medicine